Study of BMS-663513 in Patients With Advanced Cancer

Mise à jour : Il y a 5 ans
Référence : NCT00309023

Femme et Homme

Extrait

This is a Phase I/II, ascending, multi-dose study of BMS-663513, an agonistic anti-CD137 monoclonal antibody, administered every three weeks to patients with metastatic or locally advanced solid tumors.


Critère d'inclusion

  • Tumors

Liens